Clinical Report: The Importance of Mechanisms in the Relationship Between Low Cholesterol and Liver Health

Background

The management of LDL-C levels is crucial for reducing cardiovascular risk, with PCSK9 inhibition emerging as a key therapeutic strategy. Understanding the hepatic effects of low cholesterol levels is essential.

Data Highlights

In a study involving carriers of rare PCSK9 loss-of-function variants, it was found that these individuals had significantly lower LDL-C concentrations without an increased risk of liver disease (hazard ratio, 1.08; P = .80). Additionally, over a 15-year follow-up, carriers of the PCSK9 R46L variant did not experience more liver-related complications (hazard ratio, 1.12; P = .28). However, individuals with primary familial hypobetalipoproteinemia (FHBL) exhibited over a 3-fold higher risk of liver complications compared to the control population. Heterozygous FHBL-SD was linked to increased hepatic steatosis and fibrosis, indicating the need for regular hepatological surveillance. In contrast, FHBL-EC due to PCSK9 LoF variants was not associated with liver disease. Long-term safety data from PCSK9 inhibitor trials also support the safety of these therapies concerning liver health.

Key Findings

• Carriers of rare PCSK9 loss-of-function variants had significantly lower LDL-C concentrations without increased liver disease risk (hazard ratio, 1.08; P =.80).

• Over 15 years of follow-up, carriers of the PCSK9 R46L variant did not experience more liver-related complications (hazard ratio, 1.12; P =.28).

• Individuals with primary familial hypobetalipoproteinemia (FHBL) had over a 3-fold higher risk of liver complications compared to the control population.

• Heterozygous FHBL-SD is linked to increased hepatic steatosis and fibrosis, necessitating regular hepatological surveillance.

• FHBL-EC due to PCSK9 LoF variants is not associated with liver disease.

• Long-term safety data from PCSK9 inhibitor trials support the safety of these therapies concerning liver health.

Clinical Implications

Clinicians should consider the underlying mechanisms of hypocholesterolemia when evaluating liver health in patients with low cholesterol levels.

Conclusion

The evidence indicates that while low cholesterol levels can be associated with liver complications, the mechanisms involved are critical in determining risk. Ongoing research and clinical trials will further clarify the safety of PCSK9-targeting therapies.

Related Resources & Content

1. Di Costanzo et al, UK Biobank, 2023 -- The Importance of Mechanisms in the Relationship Between Low Cholesterol and Liver Health

2. Clinical Research in Cardiology — Reevaluating the Clinical Importance of HDL Cholesterol

3. Frontiers in Cardiovascular Medicine — Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation

4. The New Gastroenterologist — The Impact of Statins on Liver Health: Safe and Potentially Advantageous

5. Frontiers in Endocrinology — Interactions Between Lipid Metabolism and MAFLD: Mechanisms and Treatment Approaches

6. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia

7. The Impact of Statins on Liver Health: Safe and Potentially Advantageous

8. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

9. PCSK9 in metabolism and diseases - ScienceDirect